About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 7620 record(s)
Req # A-2019-001314
Adverse Reaction Report (AER) for Vyvanse. Report numbers: E2B_02572800, E2B_02599805, E2B_02608582, E2B_02558019, E2B_02563899.Organization: Health Canada
February 2020
Req # A-2019-001429
Adverse Reaction Report (AER). Report number: E2B_02458664.Organization: Health Canada
February 2020
Req # A-2019-001315
Adverse Reaction Report (AER) for Mesalamine, Mesalazine. Report numbers: E2B_02606624, E2B_02606638, E2B_02606640, E2B_02603286, E2B_02605383.Organization: Health Canada
February 2020
Req # A-2019-001316
Adverse Reaction Report (AER) for Mezavant / Mesalazine. Report numbers: E2B_02208881, E2B_02212530, E2B_02233941, E2B_02211053, E2B_02255487.Organization: Health Canada
February 2020
Req # A-2019-001332
Adverse Reaction Report (AER). Report numbers: 000526493, 000455277, E2B_00842622, 000684858, E2B_00955226, E2B_02186544, E2B_00196540, 000578755 , E2B_00204350, E2B_00204355.Organization: Health Canada
February 2020
Req # A-2019-001340
Adverse Reaction Report (AER). Report number: E2B_02620893.Organization: Health Canada
February 2020
Req # A-2019-001342
Adverse Reaction Report (AER). Report number: E2B_02670649.Organization: Health Canada
February 2020
Req # A-2019-001348
Adverse Reaction Report (AER) for VEDOLIZUMAB. Report numbers: 725289, 728451, E2B_02445741, E2B_02450172, E2B_02459903, E2B_02476745, E2B_02477366, E2B_02482124, E2B_02545200, E2B_02555422, E2B_02555477, E2B_02577912, E2B_02578003, E2B_02597273, E2B_02653348, E2B_02661299, E2B_02666942, E2B_02670702.Organization: Health Canada
February 2020
Req # A-2019-001349
Adverse Reaction Report (AER) for NINLARO. Report numbers: E2B_02475335, E2B_02475402, E2B_02520346, E2B_02532303, E2B_02534392, E2B_02534423, E2B_02540687, E2B_02570458.Organization: Health Canada
February 2020
Req # A-2019-001409
Adverse Reaction Report (AER). Report number: 000727851.Organization: Health Canada
February 2020